|
Contents
|
|
|
|
Laboratory
Investigations |
|
|
|
|
Ebos JM, Kerbel RS.
Antiangiogenic
therapy: impact on invasion, disease progression, and metastasis.
Nat
Rev Clin Oncol. 2011 Mar 1;8(4):210-21. Erratum in: Nat Rev Clin
Oncol. 2011 Jun;8(6):316. Nat Rev Clin Oncol. 2011;8(4):221
.JPG) Abstract |
.png)
Full
text | .png)
Reprint
| .gif)
Related articles
|
|
|
Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H,
Viñals F, Inoue M, Bergers G,
Hanahan D, Casanovas O.
Antiangiogenic therapy elicits malignant progression of tumors to increased
local invasion and distant metastasis.
Cancer Cell. 2009 Mar 3;15(3):220-31°
Abstract |
Reprint |
Related
articles
|
|
|
Astrocytoma |
|
|
|
|
Chamberlain MC, Johnston S
Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory
anaplastic astrocytoma
J Neurooncol.
2009 Feb;91(3):359-67. Epub 2008 Oct 25
Abstract
|
|
|
Sathornsumetee S, Cao Y, Marcello JE, Herndon JE
2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ,
Rich JN
Tumor angiogenic and hypoxic profiles predict radiographic response and
survival in malignant astrocytoma patients treated with bevacizumab and
irinotecan
J
Clin Oncol. 2008 Jan 10;26(2):271-8
Abstract
|
|
|
Embryonal
Tumors |
|
|
|
Bevacizumab,
Celecoxib, Cyclophosphamide, Etoposide, Fenofibrate, Thalidomide
|
Peyrl
A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech T, Dieckmann K,
Schmook MT, Haberler C, Leiss U, Slavc I.
Antiangiogenic metronomic therapy for children with recurrent embryonal
brain tumors.
Pediatr Blood Cancer. 2011 Dec 6;. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Ependymoma
|
|
|
|
|
Green
RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB.
Bevacizumab for recurrent ependymoma
Neurology. 2009 Nov 17;73(20):1677-80
Abstract
|
|
|
Glioblastoma |
|
|
|
|
Bähr O, Hattingen E, Rieger J, Steinbach JP.
Bevacizumab-induced tumor calcifications as a surrogate marker of outcome
in patients with glioblastoma.
Neuro Oncol. 2011
Sep;13(9):1020-9. Epub 2011 Jul 31.
Abstract |
Related articles
|
|
|
Chamberlain MC.
Treatment of Glioblastoma with Bevacizumab: Has a New Standard Therapy
been Defined?
CNS Drugs. 2011 Oct 1;25(10):815-8.
Abstract |
Related articles
|
|
|
Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H,
Modrusan Z, Cloughesy T.
AVAglio:
Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly
diagnosed glioblastoma multiforme.
Adv Ther. 2011 Apr;28(4):334-40.
Epub 2011 Mar 14.
Abstract |
Reprint |
Related articles
|
|
|
Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott
MW, Parsa AT, Berger MS, Aghi MK.
Neurosurgical management and prognosis of patients with glioblastoma that
progress during bevacizumab treatment.
Neurosurgery. 2011 Aug 9. [Epub
ahead of print]
Abstract |
Related articles
|
|
|
Desjardins
A,
Reardon
DA,
Peters
KB,
Herndon II
JE,
Kirkpatrick
JP,
Friedman
HS
and Vredenburgh
JJ
Survival And Toxicity Update Of The Phase 2 Trial Of Bevacizumab (Bv) In
Combination With Temozolomide (Tmz) And Radiation Therapy (Rt) Followed By
Bv, Tmz, And Irinotecan (Cpt-11) For Newly Diagnosed Glioblastoma Multiforme
(Gbm) Patients
Abstracts
from the 15th Annual Meeting of the Society for Neuro-Oncology (SNO),
November 18–21, 2010, Montreal, Quebec, Canada
Abstract |
.gif)
News
|
|
|
Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS.
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
Expert Opin Pharmacother. 2011 Apr;12(5):825-33.
Abstract |
Related articles
|
|
|
Kilickap
S, Oztoprak I, Yucel B.
Complete remission after
bevacizumab plus temozolomide in a patient with recurrent glioblastoma
multiforme.
Acta Oncol. 2011 Dec 27;. [Epub
ahead of print]
Abstract |
Related articles
|
|
|
J. Kirkpatrick, A. Desjardins, J. J. Vredenburgh, J. A. Quinn, J. N.
Rich, S. Sathornsumetee, S. Gururangan, A. H. Friedman, H. S. Friedman, D.
A. Reardon
Combination of bevacizumab, a monoclonal antibody to vascular endothelial
growth factor (VEGF), and temozolomide: Study of cases
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
(Post-Meeting Edition).
Vol 24, No 18S (June 20 Supplement), 2006: 11522
Abstract
|
News
|
|
|
Furuse
M, Kawabata S, Kuroiwa T, Miyatake SI.
Repeated treatments with bevacizumab for recurrent radiation necrosis in
patients with malignant brain tumors: a report of 2 cases
J Neurooncol. 2010 Aug 7;. [Epub ahead of print]
Abstract
|
|
|
Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH,
Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE,
Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T.
Phase
II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy
for Patients With Newly Diagnosed Glioblastoma Multiforme.
J
Clin Oncol. 2010 Dec 6. [Epub ahead of print]
Abstract |
News
|
Related articles
|
|
|
Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham
C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T.
Phase II Pilot Study of Bevacizumab in Combination With Temozolomide and
Regional Radiation Therapy for Up-Front Treatment of Patients With Newly
Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and
Tolerability
Int
J Radiat Oncol Biol Phys. 2008 Mar 20; [Epub ahead of print]
Abstract
|
|
|
Laigle-Donadey
F, Dehais C, Mazeron JJ, Sanson M
Association of radiotherapy and chemotherapy-targeted therapies in
glioblastomas
Bull Cancer. 2009 Mar 1;96(3):291-297
Abstract
|
|
|
Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE,
Jenrette JM, Cohen SC, Black P, Brady LW.
A Phase II study of anti-epidermal growth factor receptor
radioimmunotherapy in the treatment of glioblastoma multiforme
J Neurosurg. 2010 Mar 26;. [Epub ahead of print]
Abstract
|
|
|
Lou E, Turner S, Sumrall
A, Reardon DA, Desjardins A, Peters KB, Sampson JH, Friedman HS, Vredenburgh
JJ.
Bevacizumab-Induced Reversible Posterior Leukoencephalopathy
Syndrome and Successful Retreatment in a Patient With Glioblastoma.
J
Clin Oncol. 2011 Sep 6. [Epub ahead of print]
Abstract
|
Related articles
|
|
|
Mathieu
V, De Nève N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R,
Lefranc F
Combining bevacizumab with temozolomide increases the antitumor efficacy of
temozolomide in a human glioblastoma orthotopic xenograft model
Neoplasia. 2008 Dec;10(12):1383-92
Abstract |
Full Text |
Reprint
|
|
|
Moustakas
A, Kreisl TN.
New treatment options in the management of glioblastoma multiforme: a focus
on bevacizumab
Onco Targets Ther. 2010 Jun 24;3:27-38
Abstract |
Full Text |
Reprint
|
|
|
Narayana
A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, Zagzag D, Eagan P,
Gruber ML.
A clinical trial of bevacizumab, temozolomide, and radiation for newly
diagnosed glioblastoma.
J Neurosurg. 2011 Oct 28;. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Omuro AM, Delattre JY
What is the place of bevacizumab and irinotecan in the treatment of
glioblastoma and other malignant gliomas?
Curr Opin Neurol. 2008 Dec;21(6):717-719
Abstract
|
|
|
Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd,
Marcello JE, Kirkpatrick J, Sampson JH, Bailey L, Threatt S, Friedman AH,
Bigner DD, Friedman HS.
The
Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide
Followed by Bevacizumab, Temozolomide and Irinotecan for Newly Diagnosed
Glioblastoma.
Clin
Cancer Res. 2011 Apr 29. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Recurrent
Tumors
|
|
|
|
|
Ali SA, McHayleh WM, Ahmad A, Sehgal R, Braffet
M, Rahman M, Bejjani G, Friedland DM.
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series
of 13 cases
J Neurosurg.
2008 Aug;109(2):268-72
Abstract
|
|
|
Chamberlain MC.
Bevacizumab
for the treatment of recurrent glioblastoma.
Clin Med
Insights Oncol. 2011;5:117-29. Epub 2011 May 2.
Abstract |
Reprint |
Related articles
|
|
|
Chamberlain MC, Johnston SK.
Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab
J Neurooncol. 2010 Aug 1;. [Epub ahead of print]
Abstract
|
|
|
Chamberlain MC, Lassman AB, Iwamoto FM.
Patterns of relapse and prognosis after bevacizumab failure in recurrent
glioblastoma.
Neurology. 2010 Apr
13;74(15):1239-41.
Abstract |
Related articles
|
|
|
Chamberlain MC, Johnston SK
Salvage
therapy with single agent bevacizumab for recurrent glioblastoma
J Neurooncol.
2009 Jul 11. [Epub ahead of print]
Abstract
|
|
|
Chamberlain MC
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma
J Clin Oncol. 2008 Feb 20;26(6):1012-1013
Abstract |
Full Text |
Reprint
|
|
|
Chowdhary S, Wong ET
Bevacizumab combined with irinotecan for recurrent glioblastoma
multiforme-improvement over available therapy?
Nat Clin Pract Neurol. 2008 Jan 22. [Epub ahead of print]
Abstract
|
|
|
Clark AJ, Butowski NA,
Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, McDermott MW, Parsa
AT, Berger MS, Aghi MK.
Impact
of bevacizumab chemotherapy on craniotomy wound healing.
J Neurosurg. 2011 Jun;114(6):1609-16. Epub 2010 Dec 10.
Abstract
|
|
|
Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L,
Peters KB, Friedman HS, Vredenburgh JJ.
Bevacizumab
and daily temozolomide for recurrent glioblastoma.
Cancer. 2011 Jul 26. [Epub ahead of
print]
Abstract |
Related articles
|
|
|
Francesconi AB, Dupre S, Matos M, Martin D, Hughes BG, Wyld DK, Lickliter JD
Carboplatin and etoposide combined with bevacizumab for the treatment of
recurrent glioblastoma multiforme
J Clin Neurosci. 2010 Jun 9;. [Epub ahead of print]
Abstract
|
|
|
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey
LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J,
Zheng M, Cloughesy T
Bevacizumab Alone and in Combination With Irinotecan in Recurrent
Glioblastoma
J
Clin Oncol. 2009 Aug 31. [Epub ahead of print]
Abstract
|
|
|
Hasselbalch
B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, Poulsen HS,
Stockhausen MT, Lassen U.
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in
recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and
irinotecan
APMIS. 2010 Aug;118(8):585-94. Published Online: 1 Jun 2010
Abstract
|
|
|
Khasraw
M, Holodny A, Goldlust SA, Deangelis LM.
Intracranial hemorrhage in
patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering
experience.
Ann Oncol. 2011 May 4;. [Epub
ahead of print]
Abstract |
Related articles
|
|
|
Kreisl
TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman
JA, Camphausen K, Park J, Albert PS, Fine HA
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus
Irinotecan at Tumor Progression in Recurrent Glioblastoma
J Clin Oncol. 2008 Dec 29; [Epub ahead of print]
Abstract
|
|
|
Lassman AB, Iwamoto FM, Gutin PH, Abrey LE.
Patterns of relapse and prognosis after
bevacizumab (BEV) failure in recurrent glioblastoma (GBM).
2008 ASCO Annual Meeting. J Clin Oncol. 26: 2008 (May 20 suppl; abstr 2028)
Abstract
|
|
|
Nghiemphu
PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM,
Mischel PS, Nelson SF, Elashoff R, Cloughesy TF
Bevacizumab
and chemotherapy for recurrent glioblastoma: a single-institution experience
Neurology. 2009 Apr
7;72(14):1217-22
Abstract
|
|
|
Moen
MD
Bevacizumab: in previously treated glioblastoma
Drugs. 2010;70(2):181-9
Abstract
|
|
|
Norden
AD.
Bevacizumab Failure in Recurrent Glioblastoma.
Journal Watch Neurology. 2010 Jan 12.
Abstract
|
|
|
Norden AD, Drappatz J, Muzikansky A, David K,
Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY
An
exploratory survival analysis of anti-angiogenic therapy for recurrent
malignant glioma.
J Neurooncol.
2009 Apr;92(2):149-55. Epub 2008 Nov 29.
Abstract |
Reprint |
Related articles
|
|
|
Park KJ, Kano H, Iyer A, Liu X, Niranjan A, Flickinger JC, Lieberman FS, Lunsford
LD, Kondziolka D.
Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for
recurrent glioblastoma multiforme: a case-control study.
J Neurooncol. 2011 Nov 5;. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Reardon
DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon
JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS.
Phase II study of
carboplatin, irinotecan, and bevacizumab for bevacizumab
naïve,
recurrent glioblastoma.
J Neurooncol. 2011 Oct
11;. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Reardon
DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH,
McLendon RE, Herndon JE 2nd, Coan A, Threatt S, Friedman AH, Friedman HS.
Phase
2 study of carboplatin, irinotecan, and bevacizumab for recurrent
glioblastoma after progression on bevacizumab therapy.
Cancer.
2011 May 16. doi: 10.1002/cncr.26188. [Epub ahead of print]
Abstract |
Related articles
|
|
|
James J. Vredenburgh,
Annick Desjardins, David A. Reardon, Henry
S. Friedman
In Reply
Journal of Clinical Oncology, Vol 26, No 6 (February 20),
2008: pp. 1013. DOI:
10.1200/JCO.2007.15.1746
Abstract |
Full Text |
Reprint
|
|
|
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich
JN,
Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD,
Friedman AH, Friedman HS.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
J
Clin Oncol. 2007 Oct 20;25(30):4722-9.
Abstract |
Full
Text |
Reprint
|
|
|
Wefel
JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff
D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J,
Das A, Friedman HS.
Neurocognitive function in
patients with recurrent glioblastoma treated with bevacizumab.
Neuro Oncol. 2011 May 9;. [Epub
ahead of print]
Abstract |
Related articles
|
|
|
Wick
W, Weller M, van den Bent M, Stupp R
Bevacizumab
and Recurrent Malignant Gliomas: A European Perspective
J Clin Oncol.
2010 Mar 8. [Epub ahead of print]
Abstract |
Reprint
|
|
|
Wong ET, Brem S.
Taming glioblastoma: targeting angiogenesis.
J
Clin Oncol. 2007 Oct 20;25(30):4705-6.
Abstract |
Reprint |
Related articles
|
|
|
Glioma
(High-Grade) |
|
|
|
|
Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM,
Lafrankie DC, Ruland S, Quant EC, Beroukhim R, Wen PY.
Safety
of concurrent bevacizumab therapy and anticoagulation in glioma patients.
J Neurooncol.
2011 Jun 26. [Epub ahead of print]
Abstract |
Related articles
|
|
|
von Baumgarten LD, Brucker D, Tirniceru AL, Kienast Y, Grau S, Burgold S,
Herms J, Winkler F.
Bevacizumab
has differential and dose-dependent effects on glioma blood vessels and
tumor cells.
Clin
Cancer Res. 2011 Jul 25. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Recurrent
Tumors
|
|
|
|
|
Bokstein F, Shpigel S, Blumenthal DT
Treatment with bevacizumab and irinotecan for recurrent high-grade glial
tumors
Cancer. 2008 May 15;112(10):2267-73
Abstract
|
|
|
Chamberlain
MC
Emerging clinical principles on the use of bevacizumab for the treatment
of malignant gliomas
Cancer. 2010 May 28;. [Epub ahead of print]
Abstract
|
|
|
Cuneo
KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB,
Friedman HS, Willett CG, Kirkpatrick JP.
Safety and Efficacy of Stereotactic Radiosurgery and Adjuvant Bevacizumab in
Patients with Recurrent Malignant Gliomas.
Int J Radiat Oncol Biol Phys. 2011 Apr 12;. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Desjardins A, Reardon DA, Herndon JE 2nd,
Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J,
Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ.
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Clin
Cancer Res. 2008 Nov 1;14(21):7068-73
Abstract
|
|
|
Eoli
M, Calleri
A, Cuppini
L, Anghileri
E, Pellegatta
S, Prodi
E, Bruzzone
MG, Bertolini
F, Finocchiaro
G.
Circulating endothelial cells and progenitors in recurrent high-grade
gliomas treated with bevacizumab and irinotecan.
J Clin Oncol. 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 29, No 15_suppl (May 20 Supplement), 2011:2044
Abstract
|
|
|
Eoli
M, Calleri
A, Cuppini
L, Mancuso
P, Prodi
E, Pellegatta
S, Solero CL, Bruzzone
MG, Bertolini
F, Finocchiaro
G.
Levels of circulating
endothelial cells in relapsing glioblastoma patients responding to
bevacizumab.
J
Clin Oncol.
2010
ASCO Annual Meeting Proceedings
(Post-Meeting Edition).
Vol
28, No 15S (May 20 Supplement), 2010:
2067
Abstract
|
|
|
Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou
CNO, Lymberis S, Yamada Y,
Chang J, Abrey LE
Safety and Efficacy of Bevacizumab with Hypofractionated Stereotactic
Irradiation for Recurrent Malignant Gliomas
Int J Radiat Oncol Biol Phys. 2009 Jan 23. [Epub ahead of print]
Abstract
|
|
|
Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg
A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G.
O-(2-18F-Fluoroethyl)-L-Tyrosine
PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent
High-Grade Glioma.
J
Nucl Med. 2011 Jun;52(6):856-64.
Abstract |
Related articles
|
|
|
Iwamoto FM, Fine HA.
Bevacizumab for malignant gliomas.
Arch Neurol. 2010
Mar;67(3):285-8.
Abstract |
Reprint |
Related articles
|
|
|
Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul
J, Fine HA.
A phase II trial of single-agent bevacizumab in patients with recurrent
anaplastic glioma.
Neuro Oncol. 2011 Aug 24. [Epub
ahead of print]
Abstract |
Reprint
|
Related articles
|
|
|
Lorgis
V, Maura G, Coppa G, Hassani K, Taillandier L, Chauffert B, Apetoh L,
Ladoire S, Ghiringhelli F.
Relation between bevacizumab dose intensity and high-grade glioma survival:
a retrospective study in two large cohorts.
J Neurooncol. 2011 Nov 11;. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Narayana A, Kelly P, Golfinos J, Parker E,
Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P,
Gruber ML
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma:
impact on local control and patient survival
J Neurosurg.
2008 Oct 3. [Epub ahead of print]
Abstract
|
|
|
Niyazi
M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, Geisler J, la Fougère C,
Ertl L, Linn J, Siefert A, Belka C.
Irradiation
and Bevacizumab in High-Grade Glioma Retreatment Settings.
Int
J Radiat Oncol Biol Phys. 2010 Oct 27. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Norden
AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS,
Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and
patterns of recurrence
Neurology. 2008 Mar
4;70(10):779-87
Abstract |
Full Text |
Reprint
|
|
|
Peak SJ, Levin VA.
Role of bevacizumab therapy in the management of glioblastoma.
Cancer Manag Res. 2010 Apr 22;2:97-104.
Abstract |
Reprint
|
|
|
Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler
JP, Muro K, Dubner S,
Rademaker AW, Renfrow J, Bredel M
A phase 2 trial of single-agent bevacizumab given in an every-3-week
schedule for patients with recurrent high-grade gliomas
Cancer. 2010 Jul 27;. [Epub ahead of print]
Abstract
|
|
|
Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S,
Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE 2nd, Marcello JE,
Norfleet J, Friedman AH, Bigner DD, Friedman HS
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for
recurrent malignant glioma: a phase II study
Br J Cancer. 2009 Nov 17;. [Epub ahead of print]
Abstract
|
|
|
Salmaggi A, Gaviani P,
Botturi A, Lamperti E, Simonetti G, Ferrari D, Silvani A.
Bevacizumab
at recurrence in high-grade glioma.
Neurol Sci. 2011
Oct 7. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Sathornsumetee
S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe
A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA.
Phase II trial of bevacizumab and erlotinib in patients with recurrent
malignant glioma
Neuro Oncol. 2010 Aug 17;. [Epub ahead of print]
Abstract
|
|
|
Thompson EM, Dosa E, Kraemer DF, Neuwelt EA
Treatment with bevacizumab plus carboplatin for recurrent malignant
glioma
Neurosurgery. 2010 Jul;67(1):87-93
Abstract
|
|
|
Torcuator R, Zuniga R, Loutfi R, Mikkelsen T
Bevacizumab
and irinotecan treatment for progressive diffuse brainstem glioma: case
report
J Neurooncol.
2009 Jan 13. [Epub ahead of print]
Abstract
|
|
|
Verhoeff
JJ, Lavini C, van Linde ME, Stalpers LJ, Majoie CB, Reijneveld JC, van Furth
WR, Richel DJ
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
Ann Oncol
(2010) 21 (8):
1723-1727. First
published online: January 11, 2010
Abstract |
Reprint
|
|
|
J. J. Vredenburgh, A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S.
Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, A. Friedman
Bevacizumab, a monoclonal antibody to vascular endothelial growth factor
(VEGF),
and irinotecan for treatment of malignant gliomas
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
(Post-Meeting Edition).
Vol 24, No 18S (June 20 Supplement), 2006: 1506
Abstract
|
News
|
|
|
Wick
A, Dörner N, Schäfer N, Hofer S, Heiland S, Schemmer D, Platten M, Weller
M, Bendszus M, Wick W.
Bevacizumab does not increase the risk of remote relapse in malignant glioma.
Ann Neurol. 2011 Mar;69(3):586-92.
Abstract |
Related articles
|
|
|
Xu
T, Chen J, Lu Y, Wolff JE.
Effects of bevacizumab plus irinotecan on response and survival in
patients with recurrent malignant glioma: a systematic review and
survival-gain analysis
BMC Cancer. 2010 Jun 2;10(1):252. [Epub ahead of print]
Abstract |
Full Text |
Reprint
|
|
|
Zuniga RM, Torcuator R, Jain R, Anderson J,
Doyle T, Ellika S, Schultz L, Mikkelsen T
Efficacy, safety and patterns of response and recurrence in patients with
recurrent high-grade gliomas treated with bevacizumab plus irinotecan
J Neurooncol.
2008 Oct 25. [Epub ahead of print]
Abstract
|
|
|
Zustovich
F, Lombardi G, Pastorelli D, Farina P, Furini L, Manara R, Palma MD, Rotilio
A, Nicoletto O, Zagonel V.
Bevacizumab and glioblastomas, a single-centre experience: how disease
history and characteristics may affect clinical outcome.
Anticancer Res. 2010 Dec;30(12):5213-6.
Abstract |
Related articles
|
|
|
Glioma
(Low-Grade) |
|
|
|
|
Levin
VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M,
Gilbert MR, Jackson EF.
Randomized
double-blind placebo-controlled trial of bevacizumab therapy for radiation
necrosis of the central nervous system.
Int
J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1487-95.
Abstract |
Related articles
|
|
|
Metastatic
Tumors |
|
|
|
|
De
Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro
AM, Holodny AI, Lassman AB.
Efficacy and safety of bevacizumab in active brain metastases from
non-small cell lung cancer
J Neurooncol. 2010 May 4;. [Epub ahead of print]
Abstract
|
|
|
Labidi
SI, Bachelot T, Ray-Coquard I, Mosbah K, Treilleux I, Fayette J, Favier B,
Galy G, Blay JY, Guastalla JP
Bevacizumab and Paclitaxel for breast cancer patients with central nervous
system metastases: a case series
Clin Breast Cancer. 2009 May;9(2):118-21. Online Date May 11, 2009
Abstract
|
|
|
Oligodendroglioma |
|
|
|
|
Chamberlain MC, Johnston S
Bevacizumab
for recurrent alkylator-refractory anaplastic oligodendroglioma
Cancer. 2009 Apr
15;115(8):1734-43
Abstract
|
|
|
Taillibert S, Vincent LA, Granger B, Marie Y,
Carpentier C, Guillevin R, Bellanger A, Mokhtari K, Rousseau A, Psimaras D,
Dehais C, Sierra del Rio M, Meng Y, Laigle-Donadey F, Hoang-Xuan K, Sanson
M, Delattre JY
Bevacizumab
and irinotecan for recurrent oligodendroglial tumors
Neurology. 2009 May
5;72(18):1601-6
Abstract
|
|
|
Pediatric
Patients |
|
|
|
|
Recurrent
Tumors
Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S,
Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J.
Bevacizumab in recurrent high-grade pediatric gliomas
Neuro Oncol. 2010 Apr 2;. [Epub ahead of print
Abstract
|
|
|
Recurrent
Tumors
Parekh
C, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J, Dhall G.
Treatment
of children with recurrent high grade gliomas with a bevacizumab containing
regimen.
J
Neurooncol. 2010 Nov 1. [Epub ahead of print]
Abstract |
Reprint |
Related articles
|
|
|
Recurrent
Tumors
Parekh C, Jubran R, Erdreich-Epstein A,
Panigrahy A, Bluml S, Finlay J, Dhall G.
Erratum to: Treatment of children with recurrent high grade gliomas with a
bevacizumab containing regimen.
J
Neurooncol. 2010 Nov 26. [Epub ahead of print]
Abstract |
Reprint |
Related articles
|
|
|
Radiation
Necrosis
|
|
|
|
|
Levin
VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M,
Gilbert MR, Jackson EF.
Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy
for Radiation Necrosis of the Central Nervous System
Int J Radiat Oncol Biol Phys. 2010 Apr 15 [Epub ahead of print] Available
online 16 April 2010
Abstract
|
|
|
Concerns |
|
|
|
|
Aliabadi H, Vredenburgh JJ, Everson RG, Desjardins A, Friedman HS, McLendon
RE, Tucci DL, Sampson JH
Bevacizumab
fails to treat temporal paraganglioma: discussion and case illustration
J
Neurooncol. 2010 Jul;98(3):427-30. Epub 2009 Dec 19
Abstract |
Related articles
|
|
|
Chamberlain MC, Neuwelt EA, Thompson EM, Frenkel EP.
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
Neurology. 2011 Aug
23;77(8):803-4. Epub 2011 Apr 1.
Abstract |
Full
text |
Reprint
| Related articles
|
|
|
Gururangan
S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S,
Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE
Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With
Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain
Tumor Consortium Study
J Clin Oncol. 2010 May 17;. [Epub ahead of print]
Abstract
|
|
|
Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter
VE, DeAngelis LM, Lassman AB
Patterns of relapse and prognosis after bevacizumab failure in recurrent
glioblastoma
Neurology. 2009 Oct 13;73(15):1200-6
Abstract
|
|
|
Kelly PJ, Dinkin MJ, Drappatz J, O'Regan KN, Weiss SE
Unexpected late radiation neurotoxicity following bevacizumab use: a case
series
J Neurooncol. 2010 Aug 1;. [Epub ahead of print]
Abstract
|
|
|
Narayana A, Kunnakkat SD, Medabalmi P, Golfinos J, Parker E, Knopp E, Zagzag
D, Eagan P, Gruber D, Gruber ML.
Change
in Pattern of Relapse After Antiangiogenic Therapy in High-Grade Glioma.
Int
J Radiat Oncol Biol Phys. 2010 Dec 14. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Pope
WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, Huo J, Brown MS, Goldin J,
Cloughesy T.
Patterns of progression in patients with recurrent glioblastoma treated with
bevacizumab.
Neurology. 2011 Feb 1;76(5):432-7.
Abstract |
Related articles
|
|
|
Ranpura V, Hapani S, Wu S.
Treatment-Related
Mortality With Bevacizumab in Cancer Patients: A Meta-analysis.
JAMA.
2011 Feb 2;305(5):487-94.
Abstract |
News
|
Related articles
|
|
|
Thompson EM, Frenkel EP, Neuwelt EA.
The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
Neurology. 2011 Jan
4;76(1):87-93.
Abstract |
Reprint |
Related articles
|
|
|
Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders
WP, van Furth WR
Concerns
about anti-angiogenic treatment in patients with glioblastoma multiforme
BMC Cancer.
2009 Dec 16;9(1):444. [Epub ahead of print]
Abstract |
Reprint
|
|
|
Wick W, Wick A, Weiler M, Weller M.
Patterns
of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions
and Evidence.
Curr
Neurol Neurosci Rep. 2011 Feb 1. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Wong ET, Brem S.
Taming
Glioblastoma by Targeting Angiogenesis: 3 Years Later.
J
Clin Oncol. 2010 Dec 6. [Epub ahead of print]
Abstract |
Reprint |
Related articles
|
|
|
Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Schultz L, Mikkelsen T
Rebound
tumour progression after the cessation of bevacizumab therapy in patients
with recurrent high-grade glioma
J
Neurooncol. 2010 Feb 12. [Epub ahead of print]
Abstract |
Full Text |
Reprint
|
|
